Zymeworks Inc. (ZYME)
NASDAQ: ZYME · Real-Time Price · USD
26.98
+0.81 (3.10%)
At close: Apr 14, 2026, 4:00 PM EDT
27.00
+0.02 (0.07%)
After-hours: Apr 14, 2026, 6:31 PM EDT
Zymeworks Employees
Zymeworks had 264 employees as of December 31, 2025. The number of employees decreased by 22 or -7.69% compared to the previous year.
Employees
264
Change (1Y)
-22
Growth (1Y)
-7.69%
Revenue / Employee
$401,383
Profits / Employee
-$307,311
Market Cap
1.99B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 264 | -22 | -7.69% | 264 | 0 |
| Dec 31, 2024 | 286 | 8 | 2.88% | 280 | 6 |
| Dec 31, 2023 | 278 | -16 | -5.44% | 272 | 6 |
| Dec 31, 2022 | 294 | -164 | -35.81% | 291 | 3 |
| Dec 31, 2021 | 458 | 103 | 29.01% | 455 | 3 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Adaptive Biotechnologies | 624 |
| Galapagos NV | 558 |
| Agios Pharmaceuticals | 540 |
| Ocular Therapeutix | 325 |
| Capricor Therapeutics | 231 |
| Stoke Therapeutics | 170 |
| Aurinia Pharmaceuticals | 128 |
| AnaptysBio | 104 |
ZYME News
- 5 days ago - Zymeworks Announces Additional Leadership Appointments to Advance Next Phase of Growth - GlobeNewsWire
- 13 days ago - Zymeworks Appoints Kristin Stafford as Chief Financial Officer - GlobeNewsWire
- 15 days ago - Zymeworks Receives U.S. FDA Fast Track Designation for ZW191, an FRα-Targeting Antibody-Drug Conjugate - GlobeNewsWire
- 21 days ago - Zymeworks Announces Participation in Upcoming Investor Conferences - GlobeNewsWire
- 27 days ago - Zymeworks Announces Presentations for Ziihera® (zanidatamab-hrii) at 2026 AACR Annual Meeting - GlobeNewsWire
- 4 weeks ago - Zymeworks to Present Clinical and Preclinical Data on ADC Programs Including Novel RAS ADC Platform at AACR Annual Meeting - GlobeNewsWire
- 6 weeks ago - Zymeworks and Royalty Pharma Enter into $250 Million Royalty-Backed Note Financing - GlobeNewsWire
- 6 weeks ago - Zymeworks Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results - GlobeNewsWire